Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 45,127 shares, a decrease of 81.9% from the July 15th total of 248,770 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average trading volume of 210,507 shares, the short-interest ratio is currently 0.2 days.

Evogene Trading Up 9.3%

Shares of EVGN traded up $0.06 during mid-day trading on Thursday, reaching $0.67. 384,101 shares of the stock traded hands, compared to its average volume of 957,416. The company has a market cap of $5.83 million, a price-to-earnings ratio of -0.48 and a beta of 1.40. Evogene has a 1 year low of $0.37 and a 1 year high of $1.50. The firm has a fifty day moving average price of $0.53 and a 200 day moving average price of $0.73.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.33). Evogene had a negative return on equity of 158.82% and a negative net margin of 638.12%.The business had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.35 million.

Insider Activity at Evogene

In related news, Director Leon Recanati purchased 460,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was purchased at an average cost of $0.64 per share, with a total value of $294,400.00. Following the completion of the acquisition, the director directly owned 1,343,886 shares of the company’s stock, valued at approximately $860,087.04. The trade was a 52.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 7.40% of the stock is owned by insiders.

Institutional Trading of Evogene

A number of large investors have recently modified their holdings of the business. XTX Topco Ltd bought a new position in shares of Evogene in the fourth quarter worth approximately $25,000. Jane Street Group LLC lifted its position in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares during the last quarter. Finally, Citadel Advisors LLC increased its holdings in shares of Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after buying an additional 36,206 shares during the last quarter. Institutional investors own 10.40% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evogene in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.